Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 142 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: fluconazole Clear all
Completed Phase 1 Interventional Results available

A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

NCT02222922
View directory record Official record
Conditions
Neoplasms
Interventions
PF-06647020 Q3W, fluconazole, PF-06647020 Q2W, PF-06647020 combined with Avelumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
15
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Sacramento, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Not applicable Interventional

A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole

NCT00002341
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Itraconazole
Drug
Lead sponsor
Janssen, LP
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Phase 4 Interventional

Fluconazole Prophylaxis of Thrush in AIDS

NCT00001542
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, Candidiasis, Oral Candidiasis
Interventions
fluconazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects

NCT03451110
View directory record Official record
Conditions
Healthy Subjects
Interventions
lemborexant, Loestrin, famotidine, fluconazole
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Phase 1 Interventional Results available

Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

NCT02122770
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
MLN4924, Fluconazole, Itraconazole, Docetaxel, Carboplatin, Paclitaxel
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Atlanta, Georgia • St Louis, Missouri • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2019 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Phase 3 Interventional

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT04368559
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Interventions
Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®

NCT00836953
View directory record Official record
Conditions
Influenza
Interventions
Influenza virus vaccine (Pediatric formulation)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 36 Months
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Sep 1, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional

Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole

NCT00005920
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
L-743,872
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rahway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)

NCT00075803
View directory record Official record
Conditions
Lymphoma, Infection, Leukemia
Interventions
Fluconazole, Voriconazole
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
2 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
33
States / cities
Birmingham, Alabama • La Jolla, California • Stanford, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2023 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

NCT02244606
View directory record Official record
Conditions
Mycoses, Candidiasis, Invasive, Candidemia
Interventions
SCY-078, Fluconazole, Micafungin
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

Dexamethasone in Cryptococcal Meningitis

NCT00000776
View directory record Official record
Conditions
Meningitis, Cryptococcal, HIV Infections
Interventions
Flucytosine, Fluconazole, Amphotericin B, Dexamethasone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1996
U.S. locations
13
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 1, 2026, 1:43 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Protocol To Evaluate Patient Measurements After Ultrasonic Treatment

NCT01260298
View directory record Official record
Conditions
Females Scheduled to be Treated Using the MC1.
Interventions
MC1 Ultrasonic Device
Device
Lead sponsor
Sound Surgical Technologies, LLC.
Industry
Eligibility
20 Years to 50 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2011 · Synced Sep 1, 2026, 1:43 PM EDT
Enrolling by invitation Phase 3 Interventional

Rezafungin Prophylaxis in Liver Transplant

NCT06774144
View directory record Official record
Conditions
Liver Transplant Infection, Fungal Infection
Interventions
Rezafungin, Standard of care antifungal prophylaxis
Drug
Lead sponsor
Fernanda P Silveira, MD, MS
Other
Eligibility
18 Years and older
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Olomorasib (LY3537982) in Healthy Participants

NCT07439250
View directory record Official record
Conditions
Healthy
Interventions
Olomorasib, Fluconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Phase 3 Interventional

Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients

NCT00002446
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Posaconazole, Fluconazole
Drug
Lead sponsor
Schering-Plough
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
17
States / cities
Berkeley, California • San Francisco, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Not applicable Interventional Results available

The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction

NCT01505179
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 17, 2020 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Phase 3 Interventional

The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis

NCT00056368
View directory record Official record
Conditions
Candidiasis
Interventions
Anidulafungin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Sep 1, 2026, 1:43 PM EDT
Terminated Phase 4 Interventional Results available

Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)

NCT02663674
View directory record Official record
Conditions
Coccidioidomycosis
Interventions
Fluconazole, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
9
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2019 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Phase 1 Interventional

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

NCT01042704
View directory record Official record
Conditions
Myeloma
Interventions
Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up
Drug · Other
Lead sponsor
Robert Redner, MD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
22
States / cities
Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)

NCT01891331
View directory record Official record
Conditions
Candidiasis, Vulvovaginal
Interventions
VT-1161, Fluconazole
Drug
Lead sponsor
Viamet
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
8
States / cities
Lake Worth, Florida • North Miami, Florida • Brooklyn, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

NCT02734862
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
Interventions
CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Davis, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2020 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770

NCT01060566
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-770
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 15, 2010 · Synced Sep 1, 2026, 1:43 PM EDT
Terminated Phase 4 Interventional Results available

Effects of Therapy With Sulfamylon® 5% Topical Solution Compared to a Historical Control Group

NCT00634166
View directory record Official record
Conditions
Burns
Interventions
Sulfamylon® For 5 % Topical Solution, Topical Antimicrobial/Antifungal Medications
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
3 Months and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
9
States / cities
Mobile, Alabama • Redlands, California • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Sep 1, 2026, 1:43 PM EDT
Completed Phase 3 Interventional

A Comparison of Fluconazole and Amphotericin B in the Treatment of Fungal Infections

NCT00002277
View directory record Official record
Conditions
Mycoses, HIV Infections
Interventions
Fluconazole, Amphotericin B
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 1, 2026, 1:43 PM EDT